Immunological and clinical changes in allergic asthmatics following treatment with omalizumab.

摘要: IgE plays a key role in allergic asthma. We investigated whether omalizumab treatment of patients with moderate to severe asthma leads changes inflammatory mediators and clinical symptoms. This sub-study was conducted on 35 positive skin prick test (SPT) requiring daily administration beclomethasone dipropionate (500-1,000 microg), who participated multicentre, randomised, double-blind, placebo-controlled study. Omalizumab or placebo administered at 0.016 mg/kg/IgE every 4 weeks. Patients recorded peak expiratory flow, symptom score beta(2)-agonist use diaries spirometry performed each visit. beta(2)-Agonist SPT wheal reaction decreased significantly (p < 0.05). Circulating levels IL-5, IL-6, IL-8, IL-10, IL-13 s-ICAM were measured before after 16 weeks treatment. 0.01). IL-5 IL-8 the group compared baseline. The other circulating did not demonstrate any changes. Histamine release reduced Airway resistance 0.05) provocative concentration inducing 20% decrease FEV(1) before, weeks, 3 months completion Both parameters Peripheral eosinophil count These findings suggest that has potential as novel for